Beyond Inertia: Advancing T2D Care With Innovative Basal Insulin Strategies

Estimated Time
1.5 hr

Release Date
Jun 21, 2024

Expiration Date
Jun 20, 2025

Discover the forefront of diabetes care at Diabetes Dialogues LIVE, targeting the latest in once-weekly basal insulin therapy, including unique mechanism of action and pharmacokinetic/pharmacodynamic properties. Join fellow endocrinologists to unpack recent safety and efficacy data. Additionally, hear discussion about basal insulin therapy for patient care and how to best ensure adherence through effective T2D management. Delve into clinical trials outcomes, glycemic control, weight management, and hypoglycemia risks. Engage in essential scientific discourse to shape the future of diabetes treatment. Do not miss this event for an insightful blend of data and practice.

This activity is derived from the Live ISS Meeting at ENDO, originally held on June 1, 2024.


Accreditation and Disclosure Information

Target Audience
This activity is intended for academic and community health care practitioners, including endocrinologists and diabetologists, endocrinology clinical researchers, fellows, and allied health professionals (nurse practitioners, physician associates, nurses, and pharmacists) who provide care for individuals with diabetes.

Educational Objectives
After completing this CE activity, the participant should be better able to:

  • Assess the current limitations that exist with traditional insulin therapies to support the rationale for the emerging role of novel therapies with unique mechanism of action (MOA) and pharmacokinetic/ pharmacodynamic properties.
  • Evaluate the latest efficacy and safety data for new and emerging options for basal insulin therapy in T2D management, including once-weekly versus once-daily basal insulin formulations.
  • Develop a comprehensive approach to incorporate basal insulin therapy into T2D treatment plans in accordance with current guidelines, emphasizing the need for individualized care and shared decision-making approaches to facilitate improved patient outcomes.
  • Identify the importance of early patient education and the impact of non-adherence to basal insulin therapy on T2D management


  • Part 1: Barriers to Basal Insulin Therapy Initiation and Management in Type 2 Diabetes
  • Part 2: Innovations on the Horizon: Emerging Trends in Basal Insulin Therapy
  • Part 3: Strategies for Advancing T2D Care: Initiation, Integration, Collaboration, and Patient Empowerment
  • Q&A

This activity is provided by 

Accreditation, Support and Credit

AMA PRA Category 1 Credits
Accreditation Statement
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Endocrine Society and Medical Learning Institute. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians.

Physician Continuing Medical Education
The Endocrine Society designates this course for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until June 20, 2025. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 1.5 contact hours in the area of pharmacology.

Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-24-056-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.



Support Statement
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure & Conflict of Interest Policy
The Endocrine Society and Medical Learning Institute, Inc. are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures
Thomas Pieber, MD

Professor of Medicine
Head of Division of Endocrinology and Metabolism
Chair of Department of Internal Medicine
Medical University of Graz
Graz, Austria

Thomas Pieber, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board: Arecor, Eli Lilly, Sanofi, Consultant: Novo Nordisk,
Speaker Panel: Novo Nordisk, Roche

Eda Cengiz, MD, MHS

Professor of Pediatrics
Director of UCSF Pediatric Diabetes Program
University of California San Francisco Benioff Professor in Children’s Health
San Francisco, CA, USA

Eda Cengiz, MD, MHS, has a financial interest/relationship or affiliation in the form of:
Scientific Advisory Board Member/Consultant: Novo Nordisk, Eli Lilly, Adocia, Arecor, Provention Bio, Portal Insulin, MannKind

Devin Steenkamp, MD

Director of Clinical Diabetes
Section of Endocrinology, Diabetes and Nutrition
Boston Medical Center Boston University Chobanian & Avedisian School of Medicine
Boston, MA, USA

Devin Steenkamp, MD, has a financial interest/relationship or affiliation in the form of:
Consultant: Abbott Diabetes Care (compensation paid to institution)

Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from the Endocrine Society and Medical Learning Institute, Inc. do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Milay Luis Lam, has a financial interest/relationship or affiliation in the form of:
Other: The obesity society, member, chair of the clinical management section, no payment

All of the relevant financial relationships of individuals for this activity have been mitigated.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 60% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact MLI at

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website:

About This Activity
The Endocrine Society and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by an educational grant subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2024 Medical Learning Institute, Inc | All Rights Reserved